AbbVie to pay $21 billion for maker of blood cancer treatments

SHARE AbbVie to pay $21 billion for maker of blood cancer treatments
SHARE AbbVie to pay $21 billion for maker of blood cancer treatments

Abbvie Inc. plans to buy Pharmacyclics to speed up its move into making treatments for blood cancers.

The North Chicago biopharmaceutical company late Wednesday said it has agreed to a cash-and-stock deal worth about $21 billion.

Pharmacyclics, based in Sunnyvale, Calif., is the maker of Imbruvica, a treatment for blood cancer, a market estimated at $24 billion worldwide.

RELATED AbbVie reports better-than-expected 4Q earnings on Humira sales AbbVie gets approval for Parkinson’s treatment

“The acquisition of Pharmacyclics is a strategically compelling opportunity. The addition of Pharmacyclics’ talented and innovative team will add enormous value to AbbVie,” chairman and chief executive Richard A. Gonzalez, said in a statement.

“Its flagship product, Imbruvica, is not only complementary to AbbVie’s oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies and raised the standard of care for patients.”

The boards of both companies have approved the deal.

Earlier Wednesday, Pharmacyclics was reported to be close to a deal to be acquired by Johnson & Johnson. The Financial Times said J&J was expected to pay more than Pharmacyclics’ $17 billion market value, making it the largest biopharmaceutical deal this year.

At $21 billion, the AbbVie-Pharmacyclics deal is bigger than Pfizer’s $17 billion takeover of Lake Forest-based Hospira. Two other big pharmaceutical takeovers this year are Valeant’s $14.5 billion deal for Salix and Shire’s $5.2 billion purchase of NPS Pharma.

The Latest
The entertaining ‘Facing Nolan’ gets the taciturn pitcher to discuss his life and his competitive side.
NFL
The team has a waiting list of 140,000 for 81,441-seat Lambeau Field, which means a long time on the list.
Lesly Morales has been missing since late April, family said.
The Committee on Public Safety approved the mayor’s ordinance by a comfortable vote of 14 to 3 that did not reflect the barrage of concerns raised about a crackdown roundly condemned as a toothless and desperate headline-grabber that will have no impact on youth violence.